TQB2303

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TQB2303, covering 2018-03-07 to 2019-05-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]